Overall, overexpression of HER2, identified in about 20% of breast cancer, is associated with a more aggressive phenotype but, however, survival of these patients has been dramatically improved by the development of drugs targeting this receptor (trastuzumab, lapatinib, and pertuzumab) [7]. The gene discussed is ERBB2; the disease is breast cancer.